Pharmalot… Pharmalittle… Good Morning
1 CommentBy Ed Silverman // February 22nd, 2010 // 7:41 am
Hello, everyone, and welcome back from the weekend. We hope your time was relaxing and you had a chance to enjoy. Now, the routine, of course, returns. What lies in store this week? We can only guess, but to prepare, we are brewing the required cup of stimulation. Grab one yourself. Meanwhile, here are a few items to help you get moving. Good luck…
Icahn Wants Four Genzyme Board Seats (TheStreet)
USPTO Tentatively Rejects Plavix Patent (Dow Jones)
Cardinal Pays $1M Fine For Missing Drugs (Columbus Business First)
Novartis Wins FDA OK For Meningitis Vaccine (MarketWatch)
Anthera Tries IPO With No Sales Or Products (Bloomberg News)
FDA To Decide On Amgen Prolia By July (Reuters)
EU Rejects J&J Drug For Skin Infections (Associated Press)
Hologic Settles Patent Suit With J&J (Reuters)
Jennifer G.
Thank you for reporting about the warning issued to WebMD regarding its egregious error of placing profit above substance by its practice of brand promotion. WebMD’s editorial oversight should have recognized this before it hit the WebMD site. Kudos to you and Sen. Grassley for bringing to light the Cymbalta page that appeared on the WebMD site.